Table 1 Participant’s characteristics and study results

N

19

9 (8 AC, 1 CC)

Age (years)^a

37 ± 14 (20 – 60)

29 ± 8 (18 – 39)

Sex (female/male)

14/5

8/1

Race (Caucasian/other)

15/4

7/2

Hispanic (yes/no)

1/18

3/6

ICS dose (μg fluticasone)^a

117 ± 250 (0 – 1000)

85 ± 128 (0 – 267)

Baseline rescue inhaler use (puffs/week)^a

5 ± 6 (0 – 18)

7 ± 7 (0 – 20)

Baseline FEV₁ (L)^a

2.24 ± 0.51 (1.35 – 3.01)

2.31 ± 0.47 (1.75 – 3.26)

Baseline FEV₁ (%)^a

69 ± 12 (51 – 89)

69 ± 9 (55 – 84)

Change in FEV₁ after placebo (%)

1 ± 9 (-21 – 18)

−4 ± 6 (-15 – 3)

Change in FEV₁ after drug (%)^a

1 ± 5 (-11 – 9)

3 ± 5 (-3 – 12)

Change in FEV₁ after drug compared to placebo (%)^a*

−1 ± 9 (-13 – 24)

7 ± 5 (1 – 17)